Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.
about
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Serum levels of soluble CD163 ...... with nivolumab: a pilot study.
@en
Serum levels of soluble CD163 ...... with nivolumab: a pilot study.
@nl
type
label
Serum levels of soluble CD163 ...... with nivolumab: a pilot study.
@en
Serum levels of soluble CD163 ...... with nivolumab: a pilot study.
@nl
prefLabel
Serum levels of soluble CD163 ...... with nivolumab: a pilot study.
@en
Serum levels of soluble CD163 ...... with nivolumab: a pilot study.
@nl
P2093
P2860
P356
P1433
P1476
Serum levels of soluble CD163 ...... with nivolumab: a pilot study.
@en
P2093
Atsushi Otsuka
Hiroo Hata
Hiroshi Uchi
Hisako Okuhira
Kayo Tanita
Keisuke Imafuku
Koji Yoshino
Megumi Aoki
Ryota Tanaka
Sadanori Furudate
P2860
P304
15542-15551
P356
10.18632/ONCOTARGET.24509
P407
P577
2018-02-15T00:00:00Z